Novocure (NVCR) Climbs 70% After Pivotal LUNAR Study in NSCLC Met Primary Overall Survival Endpoint

January 5, 2023 7:10 AM

Novocure (NASDAQ: NVCR) Climbs ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found